

























































published: 30 June 2014
doi: 10.3389/fimmu.2014.00298
Monocytes and macrophages in pregnancy and
pre-eclampsia
Marijke M. Faas*, Floor Spaans and Paul DeVos
Immunoendocrinology, Department of Pathology and Medical Biology, Division of Medical Biology, University Medical Center Groningen, University of Groningen,
Groningen, Netherlands
Edited by:
Sinuhe Hahn, University Hospital
Basel, Switzerland
Reviewed by:
Juan Carlos Salazar, Connecticut
Children’s Medical Center, USA
Fulvio D’Acquisto, Queen Mary




of Pathology and Medical Biology,
Division of Medical Biology,
University Medical Center Groningen,
University of Groningen, Hanzeplein
1, Groningen 7913 GZ, Netherlands
e-mail: m.m.faas@umcg.nl
Preeclampsia is an important complication in pregnancy, characterized by hypertension
and proteinuria in the second half of pregnancy. Generalized activation of the inflamma-
tory response is thought to play a role in the pathogenesis of pre-eclampsia. Monocytes
may play a central role in this inflammatory response. Monocytes are short lived cells
that mature in the circulation and invade into tissues upon an inflammatory stimulus and
develop into macrophages. Macrophages are abundantly present in the endometrium and
play a role in implantation and placentation in normal pregnancy. In pre-eclampsia, these
macrophages appear to be present in larger numbers and are also activated. In the present
review, we focused on the role of monocytes and macrophages in the pathophysiology of
pre-eclampsia.
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INTRODUCTION
Preeclampsia is one of the leading complications of pregnancy,
characterized by hypertension and proteinuria and developing in
the second half of pregnancy (1, 2). Preeclampsia is suggested to
be a two stage disease: the first stage being poor placentation (3).
The second stage is the production of pro-inflammatory factors by
the diseased placenta, which activates the systemic inflammatory
response, leading to the signs of pre-eclampsia (3).
During normal pregnancy, the circulation of peripheral blood
through the placenta results in direct or indirect contact of mater-
nal immune cells with the placenta. This may activate circulating
immune cells, especially monocytes (4, 5). In pre-eclampsia, due to
production of pro-inflammatory factors from the placenta (6–9),
monocytes are even further activated and together with activation
of other inflammatory cells, such as granulocytes and endothelial
cells, finally induce the full blown syndrome of pre-eclampsia (3).
At the maternal–fetal interface, from the beginning of a healthy
pregnancy, there is an increase of innate immune cells, such as
macrophages and NK cells (10). These macrophages and NK cells
may have a local immune function, however, they also appear to
be important for placental development by promoting trophoblast
recruitment, spiral artery remodeling, and angiogenesis (11). The
present review will focus on macrophages at the maternal–fetal
interface. In normal pregnancy, most of the macrophages at the
maternal–fetal interface are M2 macrophages, i.e., immunomod-
ulatory macrophages (11). In pre-eclampsia, there appear to be
increased numbers of M1 macrophages, suggesting a role for these
macrophages in the poor placental development in pre-eclampsia.
Monocytes and macrophages may thus play an important
role in healthy pregnancy as well in the pathophysiology of pre-
eclampsia. Further insight into the role of these cells in these
conditions, may lead to a better understating of the inflammatory
response in normal pregnancy and in pre-eclampsia. Therefore,
the present paper will review the systemic and local changes in
the decidua in monocytes and macrophages and their subsets dur-
ing healthy human pregnancy and pre-eclampsia. Examples from
animal models will also be included.
MONOCYTES AND MACROPHAGES AND THEIR SUBSETS
MONOCYTES
Monocytes arise from precursors in the bone marrow and com-
prise about 5–10% of the circulating blood leukocytes. They cir-
culate in the blood for a few days before migrating into tissues to
become macrophages or dendritic cells (12). They have important
functions in homeostasis, tissue repair, and inflammation (12). It
has recently become clear that circulating monocytes are a hetero-
geneous population (12). In humans, the monocyte subsets can be
distinguished based on the expression of CD14, the lipopolysac-
charide (LPS) receptor. The main subset (comprising about 90–
95% of the monocytes) is a subset expressing high levels of CD14,
but lacking CD16 (FcγR-III) expression. Since this is the main sub-
sets and until recently thought to be the only subset, this subset is
usually called “classical subset”. The second subset of monocytes
is characterized by low expression of CD14 together with CD16.
This subset is often called the non-classical subset. More recently,
a third, intermediate subset of monocytes has been defined, called
the intermediate subset (13). This subset is characterized by high
expression of CD14 in combination with expression of CD16 and
is a separate subset of monocytes. It has been suggested that classi-
cal monocytes arise from the bone marrow and mature into non-
classical monocytes via intermediate monocytes (13, 14). These
subsets differ in many respects, including expression of adhesion
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molecules and chemokine receptors and function [reviewed in Ref.
(12, 13)]. Classical monocytes are professional phagocytes that
can generate reactive oxygen species (ROS) and produce cytokines
in response to toll-like receptor dependent activation by f.i. LPS.
Non-classical monocytes are weak phagocytes and do not gener-
ate ROS, but are more efficient producers of pro-inflammatory
cytokines after TLR dependent activation (12). This subset has
been shown to have a longer half-life and localize to both rest-
ing and inflamed tissue (12). They crawl on the luminal side
of the endothelium and survey endothelial cells and tissues for
damage and infection (13). Upon damage or infection, they may
rapidly invade the tissue and initiate the inflammatory response
(15). Non-classical monocytes have been shown to be increased in
various inflammatory diseases (13, 16, 17).
MACROPHAGES
Macrophages are located in all body tissues, where they are impor-
tant in detecting, ingesting, and processing foreign material, dead
cells, and other debris (12). Monocytes are macrophage precursors
(12); monocytes can be recruited into tissues, to replenish steady
state macrophages or can be recruited in inflammatory conditions
(12), where they mature into macrophages (or dendritic cells)
(12). Macrophages play an important role in the innate and adap-
tive immune responses to pathogens and are important mediators
of inflammatory processes (12). However, they also have anti-
inflammatory properties, as they are also involved in the resolution
of the inflammation (12). Indeed, several macrophage subsets with
distinct functions have been described. Broadly, they can be clas-
sified into two groups: M1 or classically activated macrophages,
and M2 or alternatively activated macrophages (18). These sub-
sets differ in receptor, cytokine, and chemokine expression and
in effector function (18). M1 macrophages are microbicidal and
inflammatory, M2 macrophages are immunomodulatory, which
can induce tolerance and the resolution of inflammation, and
are only weak microbicidal (18). It has been suggested that these
two populations may be extreme ends of polarization and that
macrophages may actively switch their phenotype, depending on
the environment (19).
There is debate on the fate of the different monocyte subsets; it
is unclear whether tissue macrophages are derived from a specific
monocyte subset or from either subset randomly (12). It has been
suggested that classical monocytes preferentially differentiate into
M1 macrophages, while the non-classical monocytes preferentially
differentiate into M2 macrophages during inflammation (20).
However, various studies have shown that such a strict distinction
between differentiation of classical and non-classical monocytes
may not be very likely and that it may depend on the model and
the inflammatory stimulus whether a monocyte differentiates into
an M1 or M2 macrophage (20, 21).
MONOCYTES IN PREGNANCY
During normal pregnancy, the female immune system has to adapt
to the presence of the semi-allogeneic fetus. Many changes in the
peripheral circulation have been observed, both in the specific
and innate immune response. In the specific immune response, a
decreased Th1/Th2 ratio has been observed in both T cells (22–24)
as well as in NK cells (23, 25). These changes may be associated with
changes in regulatory T cells (26, 27) and Th17 cells (27). It has
been suggested, that to compensate for such changes in the specific
immune response, also the innate immune response has to adapt to
pregnancy. This has most often been shown by increased numbers
of circulating monocytes and granulocytes, resulting in increased
number of total leukocytes during pregnancy (28–30). Here, we
will discuss changes in monocytes during healthy pregnancy and
in pre-eclampsia.
Although it has been known for a long time that leukocyte
numbers increase during pregnancy, at that time this was not rec-
ognized as a sign of generalized inflammation in pregnant women.
With the introduction of new techniques, most importantly, flow
cytometry, function and activation status of leukocytes monocyte
could be examined by measuring expression of markers of acti-
vation and production of intracellular cytokines. Moreover, the
flow cytometric analysis did not require isolation of cells from
whole blood, as measurements could be done in whole blood.
This represents the in vivo situation much better, since isolation
of leukocytes from blood may activate these cells (31). Using
the whole blood method, Sacks et al. (32) showed phenotypical
activation of monocytes during pregnancy, by showing increased
expression of the activation markers CD11b, CD14, and CD64 on
monocytes from pregnant women as compared with monocytes
from non-pregnant women. Afterward, these results have been
confirmed by others (33–35).
The monocytes are also functionally changed in pregnant
women. This has, for instance, been demonstrated by measuring
the production of oxygen free radicals (32), which is increased in
pregnant women. Although some authors have shown increased
cytokine production by non-stimulated monocytes from pregnant
women vs. non-pregnant women (34), others could not confirm
this finding and only observed cytokine production by stimulated
monocytes (8, 30). Whether stimulated cytokine production of
pregnant monocytes is increased or decreased as compared to
non-pregnant women seems to depend on the stimulus. After
stimulation with only LPS cytokine production by monocytes
from pregnant women was decreased as compared with cytokine
production by monocytes from non-pregnant women (30, 36, 37).
However, after stimulation of monocytes with both LPS and IFNγ,
monocytes of pregnant women showed increased cytokine pro-
duction as compared with monocytes from non-pregnant women
(38). Although these findings seem contradictory, they can be
explained as follows: decreased cytokine production of mono-
cytes from pregnant women following LPS stimulation is a sign
of activation of monocytes, since activated monocytes become
tolerant to LPS (39). IFNγ, however, abrogates LPS tolerance
(40). Therefore, if LPS tolerance is abrogated by IFNγ during
pregnancy, monocytes produce increased amounts of cytokines
during pregnancy. The above mentioned studies have been per-
formed in the third trimester of pregnancy and based on all
above mentioned data, it is now generally accepted that mono-
cytes are activated during pregnancy. However, little is known
about monocyte activation during the course of pregnancy. How-
ever, gradually developing monocyte activation may occur during
the course of pregnancy, since one paper showed progressive phe-
notypical activation of monocytes from the first trimester to the
third trimester (34).
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MONOCYTE SUBSETS IN PREGNANCY
In the studies presented above, monocytes have been characterized
by CD14 expression, indicating that mainly classical monocytes
have been studied in pregnancy. Recently, we conducted a study
in which we identified the three subtypes of monocytes in preg-
nant women (41). We showed a decreased number of classical
monocytes and an increased number of intermediate monocytes in
healthy pregnancy. These results are in line with the suggestion that
pregnancy is an inflammatory condition, since in other inflamma-
tory diseases, this intermediate subset has also been shown to be
increased (42, 43). Our data, however, were not in line with data
of Al-ofi et al. (44), who showed increased numbers of classical
monocytes and decreased numbers of non-classical monocytes in
pregnant vs. non-pregnant women. The reason for this difference
is unclear, but may be due to differences in experimental meth-
ods. Further studies are warranted to evaluate whether the subsets
respond differently to stimulation in pregnant and non-pregnant
women.
MONOCYTES AND PARTURITION
Parturition is associated with an inflammatory response (45). At
the end of gestation, the number of leukocytes in the uterine tissue
are increased (46). Also in the peripheral circulation just before
delivery, further phenotypical activation of monocytes in com-
parison with earlier in pregnancy has been shown (47), indicating
further activation of these cells just before delivery. In line with
this suggestion, more recently, Vega-Sanchez et al. (48) showed
differences in cytokine production of monocytes between preg-
nant women in labor and pregnant women not in labor. A role
for activated monocytes in parturition can also be deduced from
data from pre-term labor, where increased expression of activation
markers by monocytes has been observed compared with healthy
pregnancy (49).
MONOCYTES IN PRE-ECLAMPSIA
It has now been well-established that during pre-eclampsia, the
innate immune system is even further activated as compared
with normal pregnancy (50). Activation of monocytes has been
demonstrated by increased expression of inflammation associated
adhesion molecules such as CD11b, ICAM-1, and CD14 (5, 32, 51,
52). However, monocytes are not only phenotypically activated,
they also produced increased amounts of oxygen free radicals
as compared to normal pregnancy (32) and their cytokine pro-
duction also differed as compared to monocytes from normal
pregnant women (38, 53–56). As for normal pregnancy, the above
mentioned studies did not take into account the presence of mono-
cyte subsets and monocytes are generally defined as CD14 positive.
In our recent study, we observed decreased numbers of classical
monocytes and an increased numbers of intermediate monocytes
in women with pre-eclampsia as compared with normal preg-
nant women (41). Although Al-ofi et al. also showed decreased
numbers of classical monocytes, in contrast to our study, they
showed increased numbers of non-classical monocytes in pre-
eclamptic women compared with healthy pregnant women (44).
As explained above, this may be due to different techniques used,
but may also be due to a different selection of patient groups
(we exclusively included early onset pre-eclamptic women, while
Al-ofi et al. included a more heterogeneous group of pre-eclamptic
women).
POSSIBLE MECHANISMS OF MONOCYTE ACTIVATION IN PREGNANCY
AND PRE-ECLAMPSIA
The exact mechanisms involved in the activation of monocytes
during pregnancy and pre-eclampsia remain unknown. The most
obvious suggestion is that the placenta is involved. Peripheral
monocytes circulate through the placental circulation and come
into close contact with the semi-allogeneic villous syncytiotro-
phoblast (Figure 1). This may activate monocytes. This notion
is supported by the fact that monocytes become activated dur-
ing their passage through the placenta (5). It is, however, unsure
whether this activation of monocytes occurs due to direct contact,
since several soluble placental products, such as cytokines (57),
placental microparticles (58), fetal DNA (59), released into the
maternal circulation, may also activate monocytes (60).
Many factors may be involved in further activation of mono-
cytes during pre-eclampsia. Factors may be derived from the
stressed placenta, such as anti-angiogenic factors (61), pla-
cental microparticles (62), or ATP (9), which are released at
increased amounts from the pre-eclamptic placenta. These fac-
tors may activate the monocytes. Also upregulation of various
pro-inflammatory cytokines, such as TNFα, IL-1β, IL-18, in the
placenta of pre-eclamptic women has been observed (63–65). On
the other hand, decreased levels of the anti-inflammatory cytokine
IL-10 have been observed in the placenta of pre-eclamptic women
(66, 67). These increased levels of pro-inflammatory cytokines in
the pre-eclamptic placenta may be responsible for the increased
FIGURE 1 | Schematic overview of the placenta. The placenta consists of
a fetal part and a maternal part. In the fetal part of the placenta, chorionic
villi, covered with syncytiotrophoblast, bath in maternal blood of the
intervillous space. Direct or indirect contact (via soluble factors) of
monocytes with the syncytiotrophoblast may results in monocyte
activation. The maternal part of the placenta consists of decidua in which
remodeled spiral arteries are present, which take maternal blood to the
intervillous space. In the decidua fetal trophoblast, and maternal
macrophages and NK cells are present and necessary for immune
regulation and spiral artery remodeling ©ilusjessy – Fotolia.com.
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circulating levels of these cytokines in pre-eclamptic patients (68,
69). These cytokines may also activate the monocytes. Since mono-
cytes themselves are potent producers of cytokines, the activation
of monocyte by placental factors and cytokines may in turn result
in a vicious circle of monocytes activation and cytokine pro-
duction leading to persistent increased monocyte activation in
pre-eclampsia.
It appears to be important for induction of pre-eclamptic signs
how monocytes are activated. In pregnant rats, hypertension and
proteinuria can only be induced after infusion with E coli LPS
(70), not after infusion of LPS from Porphyromonas gingivalis (71),
despite the fact that monocytes are activated by this LPS (72).
This may explain why certain infections, such as urinary tract
infections or periodontitis, may increase the risk of pre-eclampsia,
while other infections, such as CMV or malaria do not increase the
risk for pre-eclampsia (73). Apparently, the immune response, and
specifically monocyte activation is different in different infections.
Differences may amongst others relate to differences in cytokine
production between states of monocytes activation, since we have
previously shown that activation of monocytes with E coli LPS or
P. gingivalis LPS resulted in different cytokine production (36).
MONOCYTES DURING PREGNANCY AND EXPERIMENTAL
PRE-ECLAMPSIA IN ANIMALS
Although it is now generally accepted that during pregnancy
monocytes are activated and that they are even further activated
during pre-eclampsia, whether this is the cause or consequence
of pre-eclampsia still remains to be shown. It is difficult to study
the role of monocytes in pregnancy and pre-eclampsia in human
subjects. Therefore, animal models are needed. A good animal
model to study innate immune responses in pregnancy is the
rat. Although not completely similar, like humans, rats have a
hemochorial placenta, showing deep trophoblast invasion into the
uterine wall (74) indicating that fetal–maternal interactions may
be similar in rat and human pregnancy. Therefore pregnancy-
induced changes in the immune response may also be similar to
human pregnancy. Indeed, similar phenotypical and functional
activation of monocytes during the course of pregnancy have been
observed in rats as compared with humans (75, 76). Moreover, in
accordance with human pregnancy, we found decreased numbers
of classical monocytes and increased numbers of non-classical
monocytes during pregnancy in this species (41).
Various rat models have suggested that activation of mono-
cytes, by LPS, ATP, or TNFα during pregnancy, induced pre-
eclampsia-like signs (70, 77, 78). Interestingly, such pre-eclampsia-
like syndromes were only induced in pregnant rats, not in non-
pregnant rats (70, 77). The pathophysiology of the LPS and ATP
induced pre-eclampsia was characterized by a pregnancy-specific
inflammatory response, characterized by persistent general (75,
76, 79) and glomerular (79, 80) inflammation, in which mono-
cytes play a major role. In the ATP model, we have shown that,
similar to human pre-eclampsia, non-classical monocytes are
increased and activated by ATP, suggesting an important role
for this subset in pre-eclampsia. Together, these animal studies
support the hypothesis that activation of monocytes in preg-
nancy may result in pre-eclampsia-like signs, such as hypertension
and proteinuria.
Based on the above data on monocytes during pregnancy and
pre-eclampsia, we suggest that factors that arise from the healthy
placenta during pregnancy induce phenotypical activation of
monocytes and induce increased maturation toward non-classical
monocytes. These factors may also affect endothelial cells directly
(Figure 2A). During pre-eclampsia, the stressed placenta starts
to produce various pro-inflammatory factors, which further acti-
vate the monocytes and further increased monocyte maturation
toward non-classical monocytes. Monocyte activation results in
monocyte cytokine production.Via a vicious circle, these cytokines
may further activate the monocytes themselves as well as the
FIGURE 2 | Schematic overview of the role of monocytes during healthy
pregnancy (A) and pre-eclampsia (B). During healthy pregnancy, placental
factors (1) activate monocytes (2) and may affect endothelial cells (2) and
induce increased maturation of classical monocytes toward non-classical
monocytes (3). During pre-eclampsia, more and other soluble factors are
produced from the stressed placenta (1), resulting in further activation of
monocytes and endothelial cells (2) and further maturation of classical
monocytes toward non-classical monocytes (3). Numbers non-classical
monocytes are increased and they may play an important role in this
inflammatory process, since they are known to produce increased numbers
of cytokines upon activation (4). These cytokines further activate the
monocytes (5) as well as endothelial cells (5). This vicious circle of activation
of monocytes and endothelial cells finally results in the symptoms of
pre-eclampsia, such as hypertension and proteinuria.

























































Faas et al. Monocytes and macrophages in pregnancy and pre-eclampsia
endothelial cells, finally resulting in the signs of pre-eclampsia,
such as proteinuria and hypertension (Figure 2B).
DECIDUAL MACROPHAGES
Macrophages are already present in the non-pregnant
endometrium, although in low numbers (81). Since their num-
bers fluctuate during the menstrual cycle (81, 82), it seems likely
that these are under hormonal control (83). After fertilization, the
number of uterine macrophages increase, due to expression of
various chemokines (84) and during pregnancy macrophages are
abundantly present in the decidua at all times of pregnancy (85).
During pregnancy, they comprise about 20–30% of all decidual
leukocytes (86, 87). The number of decidual macrophages may
vary with gestational age being highest in the first and second
trimester (88). Macrophages in the decidua are usually associ-
ated with spiral arteries and glands as well as with extravillous
trophoblast (86, 89), but are also found in the myometrium
(85). When the presence of macrophages in the decidua was
first discovered, it was suggested that these cells were recruited
as the result of an immune response to the semi-allogeneic fetus
(90). However, it is now generally accepted that macrophages,
and other immune cells present in the decidua, are necessary
for successful implantation (85). Various studies have focused
on specific functions of macrophages in the decidua and it
has been suggested that the decidual macrophages have various
roles during pregnancy, mainly in placentation (91), but they
may also play a role in protecting the fetus against intrauterine
infection (92).
DECIDUAL MACROPHAGES IN EARLY PREGNANCY
Most of the studies on macrophages in the decidua have been per-
formed in early pregnancy. At this time of pregnancy, macrophages
are located near the spiral arteries during trophoblast invasion and
spiral artery remodeling (86, 89). The role of macrophages in spiral
artery remodeling was further emphasized by the fact that they are
present even before the presence of extravillous trophoblast (93).
At that time, disruption and disorganization of vascular smooth
muscle cells and endothelial cells was also observed (93). This
suggests that macrophages may be important in the very early
phases of spiral artery remodeling, preparing the spiral arteries
for further remodeling by trophoblast cells (93). Their suggested
role in vascular remodeling is in accordance with the findings
of production of factors associated with angiogenesis and tissue
remodeling by these cells (94, 95). Indeed macrophages, which
were MMP 9 positive, and which were shown to have phago-
cytotic capacities were found to infiltrate spiral arteries during
remodeling (96). Macrophages have also been shown to be impor-
tant for clearance of apoptotic cells in the decidua (97). Apoptosis
is an important process during spiral artery remodeling and tro-
phoblast invasion. During these processes, apoptotic trophoblast
cells (98) as well apoptotic cells in the vascular wall that is being
remodeled have been observed (93). By engulfment of the apop-
totic cells, macrophages prevent the release of pro-inflammatory
substances from the apoptotic cells into the decidua [reviewed in
Ref. (97)].
Decidual macrophages have mainly been classified as M2-
like macrophages, i.e., immunomodulatory macrophages (99).
Although they express many markers of M2 macrophages, such
as CD206, CD163, and DC-sign (100–102), they appeared not to
be typical M2 macrophages, since they are not induced by Th2
cytokines, such as IL4, but by M-CSF and IL-10 (102). These
data are in line with the abundant presence of M-CSF and IL-
10 in the decidua (103–105). The M2 phenotype is most likely
due to hypermethylation of genes encoding markers of classical
activation and hypomethylation of genes encoding markers for
non-classical activation (106). Next to the typical M2 cytokine
gene expression, these decidual macrophages also showed gene
expression for inflammatory cytokines such as IL-6 and TNFα
(102, 107). The production of pro-inflammatory cytokines by
decidual macrophages may also be explained by the presence of
two macrophage subpopulations in the early decidua (107). One
of these subsets may be a more pro-inflammatory subset, since this
subset expressed genes associated with inflammation. The other
subset, which was higher in number, expressed genes associated
with extracellular matrix formation, networking, communication,
and growth (107).
Apart from the putative role of M-CSF and IL-10 in induc-
tion of M2 macrophages in the decidua, other factors have also
been suggested to be involved in inducing/maintaining the M2
phenotype in decidual macrophages. Decidual macrophages have
been shown to express inhibitory receptors immunoglobulin like
transcript (ILT)2 and ILT4 (108). These receptors can bind to
HLA-G expressed on invading extravillous trophoblast (108),
after which a negative signal is delivered to the macrophages,
resulting in tolerance to the trophoblast and the induction of
anti-inflammatory cytokines. It has also been suggested that the
engulfment of the apoptotic cells induced an immunosuppressive
and anti-inflammatory phenotype of the macrophages (97). Not
only the phagocytosis of apoptotic cells, but also the phagocyto-
sis of trophoblast cell debris at the maternal–fetal interface may
be associated with the M2 phenotype of macrophages (109–111).
In addition, as it has been suggested that non-classical mono-
cytes preferentially differentiate into M2 macrophages (20), it
may be speculated that the increased numbers of non-classical
monocytes in the circulation during pregnancy (41), results in
increased invasion of these cells into the decidua to become M2
macrophages.
DECIDUAL MACROPHAGES IN LATE PREGNANCY
Macrophages are present in the decidua throughout pregnancy
until the end of pregnancy,although their numbers may decrease at
the end of pregnancy (88). The exact role of decidual macrophages
at the end of pregnancy remains to be established, it seems,
however, likely that they are still involved in immunoregu-
lation and clearance of apoptotic cells. Indeed, many of the
macrophages present in the decidua at the end of pregnancy,
appeared to be M2 macrophages (112). The potential protective
effect of M2 macrophages for the fetus was recently shown by
van Schonkeren et al., who showed the presence of an inflam-
matory lesion in placentae from women who underwent egg
donation (113). This lesion consisted of maternal cells, express-
ing high levels of CD14 and CD163, suggesting the presence
of M2 macrophages. These lesions appeared to protect against
pre-eclampsia (113).
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DECIDUAL MACROPHAGES IN PRE-ECLAMPSIA
Preeclampsia is associated with defective trophoblast invasion and
spiral artery remodeling: while in healthy pregnancy, spiral artery
remodeling extends into the myometrium, in pre-eclampsia, spiral
artery remodeling can only be found in the decidua (3). Unfor-
tunately, not very many studies focused on macrophages in the
decidua in pre-eclampsia. Most of the studies in pre-eclampsia
were obviously performed after delivery of the placenta. Some
of the studies reported decreased numbers of macrophages in
the decidua of pre-eclamptic patients (114, 115). Most of the
studies, however, found increased numbers of macrophages in
pre-eclamptic patients (112, 116–118). These data may not neces-
sarily be conflicting, since not only different methods were used
(Williams and Burk performed a flow cytometric study, while
the other studies were immunohistochemical studies), also dif-
ferent antibodies were used. Increased numbers of macrophages
in the decidua of pre-eclamptic patients appears to be in line with
increased presence of macrophage chemotactic factors, such as
M-CSF, IL-8, and MCP-1 (119–121) in pre-eclamptic patients.
Not only numbers of macrophages were found to be different in
pre-eclamptic patients, macrophages may also be differently acti-
vated in pre-eclampsia (120–122). This may be in line with the
presence of increased pro-inflammatory cytokines (63–65) and
decreased anti-inflammatory cytokines in the placenta of pre-
eclamptic women (66, 67). More recently, it has been shown that
in the decidua of pre-eclamptic women decreased numbers of M2
macrophages are present (112). Differences in macrophage num-
bers may be regional, since increased numbers of macrophages
were found around the spiral arteries of pre-eclamptic patients
(120, 121). The presence of macrophages in the spiral arteries
may be associated with the development of acute artherosis (120).
Acute artherosis is a process mainly seen in poorly remodeled spi-
ral arteries at the end of pregnancy, characterized by the presence
of subendothelial CD68 positive foam cells (123). Its presence is
associated with adverse fetal and maternal outcome (124).
The question remains whether the increased presence of
macrophages in the decidua of pre-eclamptic women is the
cause or the result of pre-eclampsia. This question is difficult
to answer, due to the difficulties of obtaining material from
early decidua of women who later in pregnancy developed pre-
eclampsia. However, recently we have shown that in early decidua
from women who later developed pregnancy-induced hyperten-
sion (PIH) (including pre-eclampsia) CD68 mRNA expression was
increased (125), suggesting increased numbers of macrophages
in the early decidua of women who later develop hyperten-
sion in pregnancy. Moreover, the CD206/CD68 mRNA ratio
was decreased in PIH women, suggesting that decreased num-
bers of M2 macrophages are present in the decidua of women
who later develop pregnancy-induced hypertension (125). The
increased numbers of macrophages, with decreased numbers of
M2 macrophages may thus already be present before the onset pre-
eclampsia and therefore suggest a role for macrophages in defec-
tive trophoblast invasion and spiral artery remodeling. Recent
in vitro data showed that macrophages migrate toward invading
trophoblast (126), while other groups have shown that activated
macrophages in vitro are able to inhibit trophoblast invasion and
spiral artery remodeling (127, 128). In vivo, data have shown that
there is a reciprocal presence of trophoblast cells and macrophages
FIGURE 3 | Schematic overview of the role of decidual macrophages in
pregnancy (A) and pre-eclampsia (B). During normal pregnancy, M2-like
macrophages are present around spiral arteries and play a role in remodeling
of these arteries by producing various factors associated with angiogenesis
and tissue remodeling (such as MMP and VEGF). They also play a role in
immunomodulation, for instance by producing IL-10. During pre-eclampsia,
increased numbers of M1-like macrophages are found. They may produce
pro-inflammatory cytokines, such as TNFα, IL-1β, or IL-18.
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in the spiral arteries of both healthy and pre-eclamptic women
(121). Therefore the increased numbers of macrophages in and
around spiral arteries of pre-eclamptic women (121) may inhibit
spiral artery remodeling.
Since it is difficult to study the role of macrophages in pre-
eclampsia in humans, animal models may help in understanding
critical questions. Studying whether trophoblast invasion and
spiral artery remodeling is associated with macrophages in ani-
mal models for pre-eclampsia may shed light on the question
whether increased numbers of macrophages in the decidua are
the cause or the result of pre-eclampsia. In an animal model
for pre-eclampsia induced by multiple doses of LPS in pregnant
rats, decreased trophoblast invasion and spiral artery remodeling
after LPS was associated with increased numbers of macrophages.
We studied this subject and showed increased invasion of acti-
vated macrophages in the mesometrial triangle (the equivalent of
the placental bed in humans) before defective trophoblast inva-
sion and spiral artery remodeling (129). This appears to be in
line with the sparse human data and suggests a role for activated
macrophages in the pathophysiology of pre-eclampsia.
M2-like macrophages are thus abundantly present in the
decidua of healthy pregnant women. They are observed in the
presence of spiral arteries and extravillous trophoblast cells and
may play a role in spiral artery remodeling by producing factors
associated with angiogenesis and tissue remodeling, such as MMPs
and VEGF (Figure 3A). During pre-eclampsia, increased num-
bers of decidual macrophages are observed, which may be of the
M1 phenotype and therefore produce pro-inflammatory cytokines
(Figure 3B). These activated macrophages may affect spiral arter-
ies and may induce acute artherosis, affecting the placental blood
circulation.
SUMMARY
Monocytes and macrophages play important roles in pregnancy
and pre-eclampsia. Monocyte activation and increased numbers
of non-classical monocytes, is important for normal pregnancy.
Monocyte derived macrophages, especially M2-like macrophages
(which may be derived from non-classical monocytes) in the
decidua in healthy pregnancy play an important role in blastocyst
implantation, trophoblast invasion, and spiral artery remodeling
as well as in defense against infection and in immunomodula-
tion (Figure 4). During pre-eclampsia, decreased spiral artery
remodeling results in increased production of soluble factors
(or different factors), inducing further activation of both classi-
cal and non-classical monocytes and further maturation toward
non-classical monocytes. These placental factors as well as the
activated monocytes also induce activation of endothelial cells.
Activated monocytes (both classical and non-classical monocytes)
may invade into the decidua, resulting in increased numbers of
M1-like macrophages in the decidua of pre-eclamptic women
(Figure 4). The M1-like macrophages may affect the spiral arteries,
by for instance inducing acute artherosis. This may further affect
the placental blood circulation and stress the placenta.
Unfortunately, most studies on monocytes and macrophages
in pre-eclampsia have been performed during pre-eclampsia.
Although we do believe that monocytes and decidual macrophages
do play a role in inducing the maternal symptoms of pre-
eclampsia, it is relatively unknown whether monocytes and
FIGURE 4 | Summary of monocytes and macrophages in
pregnancy and pre-eclampsia. In healthy pregnancy, soluble factors
from the villous trophoblast activate circulating monocytes, induce
maturation of classical monocytes toward non-classical monocytes and
affect endothelial cells. Non-classical monocytes will invade into the
decidua to become M2-like macrophages to support healthy
placentation and immunomodulation. During pre-eclampsia, decreased
remodeling of the spiral arteries will results in a stressed placenta,
which produces increased amounts or different soluble factors as
compared with healthy pregnancy. The soluble factors will further
activate the monocytes, induce further maturation of classical
monocytes toward non-classical monocytes and activate endothelial
cells. Activated monocytes, by f.i. producing cytokines, further affect
monocytes and endothelial cells. This vicious circle of monocyte and
endothelial cell activation results in the maternal symptoms of
pre-eclampsia, i.e., hypertension and proteinuria. Moreover, activated
classical and non-classical monocytes may invade into the decidua to
develop into M1-like and M2-like macrophages, resulting in increased
numbers of M1-like macrophages in the pre-eclamptic decidua. The
M1-like macrophages may affect the spiral arteries resulting in f.i. acute
atherosis, thereby further affecting the placental blood circulation.
decidual macrophages do also play a role in the aberrant spiral
artery remodeling early in pregnancy. The question thus remains
as to what induces the aberrant spiral artery remodeling? Future
studies should therefore not only focus on the three monocyte sub-
sets in pregnancy and pre-eclampsia, but also on the relationship
between the circulating monocyte subsets and macrophages in the
decidua. Moreover, since data on macrophages in the decidua in
and before pre-eclampsia are relatively scarce future studies should
therefore also focus on macrophage function and phenotype in
and before pre-eclampsia.
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